CA2865282A1 - Elevated psma identifies lethal prostate cancers - Google Patents
Elevated psma identifies lethal prostate cancers Download PDFInfo
- Publication number
- CA2865282A1 CA2865282A1 CA2865282A CA2865282A CA2865282A1 CA 2865282 A1 CA2865282 A1 CA 2865282A1 CA 2865282 A CA2865282 A CA 2865282A CA 2865282 A CA2865282 A CA 2865282A CA 2865282 A1 CA2865282 A1 CA 2865282A1
- Authority
- CA
- Canada
- Prior art keywords
- psma
- imaging
- expression
- agent
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Reproductive Health (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nuclear Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602900P | 2012-02-24 | 2012-02-24 | |
| US61/602,900 | 2012-02-24 | ||
| PCT/US2013/000045 WO2013126147A2 (en) | 2012-02-24 | 2013-02-22 | Elevated psma identifies lethal prostate cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2865282A1 true CA2865282A1 (en) | 2013-08-29 |
Family
ID=49003541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2865282A Abandoned CA2865282A1 (en) | 2012-02-24 | 2013-02-22 | Elevated psma identifies lethal prostate cancers |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130225541A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3064945A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6501524B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2865282A1 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1205788A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2013126147A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865774A1 (en) * | 2012-02-28 | 2013-09-06 | Cornell University | Psma as a biomarker for androgen activity in prostate cancer |
| EP4636783A3 (en) * | 2016-10-27 | 2025-12-24 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (gui) applications |
| EP3571221A2 (en) | 2017-01-20 | 2019-11-27 | Juno Therapeutics GmbH | Cell surface conjugates and related cell compositions and methods |
| MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
| US12602772B2 (en) | 2018-01-08 | 2026-04-14 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| JP7568628B2 (ja) | 2019-01-07 | 2024-10-16 | エクシーニ ディアグノスティクス アーべー | プラットホーム非依存の全身画像セグメント化のためのシステムおよび方法 |
| CA3136127A1 (en) | 2019-04-24 | 2020-10-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated and interactive analysis of bone scan images for detection of metastases |
| US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| AU2021244617A1 (en) | 2020-03-26 | 2022-11-10 | Migdalia FORT | Ultraviolet radiation treatments |
| US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| US12597127B2 (en) | 2021-10-08 | 2026-04-07 | Exini Diagnostics Ab | Systems and methods for automated identification and classification of lesions in local lymph and distant metastases |
| CN119791845B (zh) * | 2025-01-03 | 2026-05-08 | 北京大学第一医院(北京大学第一临床医学院) | 一种降低前列腺根治性切除术后切缘阳性的治疗设备 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2436408A1 (en) * | 2001-02-07 | 2002-12-12 | Beth Israel Deaconess Medical Center | Modified psma ligands and uses related thereto |
| CA2447695C (en) * | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| ES2314272T3 (es) * | 2003-01-10 | 2009-03-16 | Millennium Pharmaceuticals, Inc. | Metodos para el diagnostico y el tratamiento del cancer. |
| US7560531B2 (en) * | 2003-05-29 | 2009-07-14 | Diadexus, Inc. | Cln101 antibody compositions and methods of use alone and in combination with prostate specific antigen and other cancer markers |
| WO2008050255A2 (en) * | 2006-10-25 | 2008-05-02 | Koninklijke Philips Electronics N. V. | Contrast agents for detecting prostate cancer |
| WO2009046294A2 (en) * | 2007-10-03 | 2009-04-09 | Cornell University | Treatment of proliferative disorders using antibodies to psma |
| WO2009127046A1 (en) * | 2008-04-14 | 2009-10-22 | Proscan Rx Pharma Inc. | Prostate specific membrane antigen antibodies and antigen binding fragments |
| CN102308212A (zh) * | 2008-12-04 | 2012-01-04 | 加利福尼亚大学董事会 | 用于确定前列腺癌诊断和预后的材料和方法 |
| JP5906090B2 (ja) * | 2009-02-17 | 2016-04-20 | コーネル・リサーチ・ファンデーション・インコーポレイテッドCornell Research Foundation, Incorporated | 癌の診断のための方法およびキットならびに治療価の推定 |
| US8772226B2 (en) * | 2009-03-17 | 2014-07-08 | The Johns Hopkins University | Methods and compositions for the detection of cancer |
-
2013
- 2013-02-22 EP EP16166503.9A patent/EP3064945A1/en not_active Withdrawn
- 2013-02-22 CA CA2865282A patent/CA2865282A1/en not_active Abandoned
- 2013-02-22 US US13/773,857 patent/US20130225541A1/en not_active Abandoned
- 2013-02-22 HK HK15106199.9A patent/HK1205788A1/xx unknown
- 2013-02-22 EP EP13752566.3A patent/EP2817629A4/en not_active Withdrawn
- 2013-02-22 JP JP2014558737A patent/JP6501524B2/ja not_active Expired - Fee Related
- 2013-02-22 WO PCT/US2013/000045 patent/WO2013126147A2/en not_active Ceased
-
2017
- 2017-05-15 US US15/595,533 patent/US20180088120A1/en not_active Abandoned
-
2019
- 2019-03-19 JP JP2019050913A patent/JP2019144254A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2817629A4 (en) | 2016-01-13 |
| US20130225541A1 (en) | 2013-08-29 |
| HK1205788A1 (en) | 2015-12-24 |
| JP6501524B2 (ja) | 2019-04-17 |
| JP2019144254A (ja) | 2019-08-29 |
| US20180088120A1 (en) | 2018-03-29 |
| JP2015513083A (ja) | 2015-04-30 |
| EP2817629A2 (en) | 2014-12-31 |
| EP3064945A1 (en) | 2016-09-07 |
| WO2013126147A2 (en) | 2013-08-29 |
| WO2013126147A3 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180088120A1 (en) | Elevated PSMA Identifies Lethal Prostate Cancers | |
| Donato et al. | Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology | |
| Sadeghi-Naini et al. | Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture | |
| De Bree et al. | Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma | |
| Créhange et al. | Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm | |
| Song et al. | Polyamine-targeting gefitinib prodrug and its near-infrared fluorescent theranostic derivative for monitoring drug delivery and lung cancer therapy | |
| Kinoshita et al. | Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer | |
| HK1223847A1 (zh) | 使用spect/ct分析进行癌症分期的方法 | |
| Khandani et al. | Positron emission tomography in renal cell carcinoma: an imaging biomarker in development | |
| Liu et al. | PET/CT using 68Ga‐PSMA‐617 versus 18F‐fluorodeoxyglucose to differentiate low‐and high‐grade gliomas | |
| Zhou et al. | Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma | |
| Wang et al. | Application of near-infrared fluorescence imaging in the accurate assessment of surgical margins during breast-conserving surgery | |
| Dong et al. | 18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer | |
| Sarkaria et al. | Intraoperative molecular imaging with pafolacianine: histologic characteristics of identified nodules | |
| Brassell et al. | Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer | |
| Houvast et al. | Prediction of Biomarker Expression on Primary Pancreatic Ductal Adenocarcinoma Tissues Using Fine-Needle Biopsies: Paving the Way for a Patient-Tailored Molecular Imaging Approach: RD Houvast et al. | |
| Mishra et al. | Advanced and futuristic approaches for breast cancer diagnosis | |
| Zhou et al. | Value of 11C-Choline PET/CT-based multi-metabolic parameter combination in distinguishing early-stage prostate cancer from benign prostate diseases | |
| Patel et al. | The challenges of integrating molecular imaging into the optimization of cancer therapy | |
| Jiang et al. | Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2 | |
| Kang et al. | Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression | |
| Greco et al. | Impact of the diagnostic methods on the therapeutic strategies | |
| Hafez et al. | Dynamin-2 and Angiopoietin-like protein 2 as novel prognostic markers in papillary thyroid carcinoma | |
| JP7246731B2 (ja) | 膵癌の予後マーカー、膵癌の予後診断キット及び膵癌の予後を予測するための方法 | |
| Wang et al. | Dan Zeng1, Jiayan Zhang1, Zuhua Song1, Qian Li1, Dan Zhang1, Xiaojiao Li1, Youjia Wen1, Xiaofang Ren1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180222 |
|
| FZDE | Discontinued |
Effective date: 20201008 |